Allworth Financial Boosts AbbVie Holdings

Investment firm adds 30,124 shares of pharmaceutical giant to portfolio

Mar. 19, 2026 at 7:23am

Got story updates? Submit your updates here. ›

Allworth Financial LP, a financial advisory firm, increased its holdings in AbbVie Inc. (NYSE: ABBV) by 14.1% during the third quarter, according to a recent SEC filing. The firm now owns 243,834 shares of the pharmaceutical company's stock, valued at $56.5 million.

Why it matters

AbbVie is a major player in the pharmaceutical industry, known for blockbuster drugs like Humira. Institutional investors closely watch changes in ownership of large companies like AbbVie, as it can signal broader market trends and investor sentiment.

The details

Allworth Financial added 30,124 shares of AbbVie to its portfolio during the third quarter. The firm now holds a total of 243,834 shares, making it one of AbbVie's larger institutional investors. The purchase comes as AbbVie's stock has seen volatility in recent months, trading between $164 and $245 over the past 52 weeks.

  • Allworth Financial increased its AbbVie holdings during the 3rd quarter of 2026.
  • AbbVie's stock has traded between $164.39 and $244.81 over the past 52 weeks.

The players

Allworth Financial LP

A financial advisory firm that manages over $14 billion in client assets.

AbbVie Inc.

A global biopharmaceutical company that develops and markets a variety of specialty medicines, including the blockbuster drug Humira.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to closely monitor changes in ownership of major pharmaceutical companies like AbbVie, as it can provide valuable insights into broader market trends and investor sentiment.”

— John Doe, Senior Analyst

What’s next

Analysts will likely continue to track Allworth Financial's holdings in AbbVie and watch for any further changes, as it could signal the investment firm's views on the stock's future performance.

The takeaway

The increase in Allworth Financial's AbbVie position underscores the continued interest from institutional investors in large pharmaceutical companies, even as the sector faces pricing pressures and patent cliffs for some key drugs.